StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE) Risk/Reward Seems Favorable, But Not Enough for Upgrade - BMO
January 31, 2019 12:21 PM
BMO Capital analyst Alex Arfaei said Pfizer's (NYSE: PFE) risk/reward in PFE remains favorable, but given the stock's strong performance ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Pfizer (PFE) Reports Positive CHMP Opinion for Vizimpro (dacomitinib) Positive CHMP Opinion for Vizimpro (dacomitinib) for 1st-Line Treatment of Adult Patients
February 1, 2019 9:21 AM